Alkermes (ALKS) Other Non-Current Assets (2011 - 2026)
Alkermes (ALKS) posted quarterly Other Non-Current Assets of $62.0 million for Q2 2026, up 211.43% year-over-year from $19.9 million in Q2 2025, and up 4.45% quarter-over-quarter from $59.4 million in Q1 2026.
Alkermes (ALKS) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other Non-Current Assets for 16 consecutive years, with $62.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 211.43% year-over-year to $62.0 million; the TTM figure through Jun 2026 stood at $62.0 million (up 211.43% YoY), while the FY2025 annual figure was $49.1 million, up 197.52% from the prior year.
- Other Non-Current Assets rose to $62.0 million in Q2 2026 per ALKS's latest filing, from $59.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $62.0 million in Q2 2026 and bottomed at $10.7 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $22.9 million across 5 years, with a median of $16.4 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 69.49% — and 2026, when it surged 223.14%.
- Alkermes' Other Non-Current Assets stood at $37.8 million in 2022, then plunged by 69.49% to $11.5 million in 2023, then surged by 43.24% to $16.5 million in 2024, then soared by 197.52% to $49.1 million in 2025, then rose by 26.28% to $62.0 million in 2026.
- Business Quant data shows ALKS's Other Non-Current Assets at $62.0 million in Q2 2026, $59.4 million in Q1 2026, and $49.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.00 Mn |
| Mar 31, 2026 | 59.36 Mn |
| Dec 31, 2025 | 49.10 Mn |
| Sep 30, 2025 | 19.66 Mn |
| Jun 30, 2025 | 19.91 Mn |
| Mar 31, 2025 | 18.37 Mn |
| Dec 31, 2024 | 16.50 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.52 Mn |
| Dec 31, 2023 | 11.52 Mn |
| Sep 30, 2023 | 11.29 Mn |
| Jun 30, 2023 | 14.54 Mn |
| Mar 31, 2023 | 14.91 Mn |
| Dec 31, 2022 | 37.76 Mn |
| Sep 30, 2022 | 10.98 Mn |
| Jun 30, 2022 | 11.57 Mn |
| Mar 31, 2022 | 10.66 Mn |
| Dec 31, 2021 | 27.46 Mn |
| Sep 30, 2021 | 16.77 Mn |